Exelixis (EXEL) Asset Writedowns and Impairment (2025)
Exelixis' (EXEL) quarterly Asset Writedowns and Impairment came in at $100000.0 in Q1 2025.
Exelixis (EXEL) Asset Writedowns and Impairment (2025) Analysis & Trends
Exelixis' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $100000.0 for Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - |
| 10 | Exelixis | 14.62 Bn | 13.85 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 3, 2025 | 100,000.00 |
| Jan 3, 2025 | 100,000.00 |